Jin H, Yang R, Gillett N, Clark R G, Ko A, Paoni N F
Department of Cardiovascular Research, Genentech, Inc., South San Francisco, California 94080, USA.
J Cardiovasc Pharmacol. 1995 Sep;26(3):420-5. doi: 10.1097/00005344-199509000-00012.
The effects of growth hormone (GH) plus insulin-like growth factor-1 (IGF-1) were tested in an experimental model of cardiac failure treated with chronic angiotensin-converting enzyme (ACE) inhibition. Myocardial infarction was induced in rats by left coronary artery ligation. Two weeks after ligation, the animals received either captopril (2 g/L in drinking water) or water for 3 months. The rats were then given either GH (2 mg/kg/day) plus IGF-1 (2 mg/kg/day) or vehicle for 14 days. Captopril treatment decreased mean arterial pressure (MAP), left ventricular end-diastolic pressure (LVEDP) and systemic vascular resistance (SVR) (p < 0.05), and increased cardiac index (CI) and stroke volume index (SVI) (p < 0.05). GH/IGF-1 or captopril+GH/IGF-1 treatment decreased MAP, LVEDP, and SVR (p < 0.05), and increased left ventricular maximum dP/dt, CI, and SVI (p < 0.05). The increases in CI and SVI were significantly greater in the captopril+GH/IGF-1-treated animals than in those treated with captopril alone (p < 0.05). The beneficial effect of captopril in reducing cardiac hypertrophy was preserved in the captopril+GH/IGF-1 group. The results indicate that GH/IGF-1 and captopril can improve cardiac performance in congestive heart failure by independent and complementary mechanisms.
在慢性血管紧张素转换酶（ACE）抑制治疗的心力衰竭实验模型中，测试了生长激素（GH）加胰岛素样生长因子-1（IGF-1）的效果。通过左冠状动脉结扎诱导大鼠心肌梗死。结扎两周后，动物接受卡托普利（饮用水中2 g/L）或水，持续3个月。然后给大鼠注射GH（2 mg/kg/天）加IGF-1（2 mg/kg/天）或赋形剂，持续14天。卡托普利治疗降低了平均动脉压（MAP）、左心室舒张末期压力（LVEDP）和全身血管阻力（SVR）（p < 0.05），并增加了心脏指数（CI）和每搏量指数（SVI）（p < 0.05）。GH/IGF-1或卡托普利+GH/IGF-1治疗降低了MAP、LVEDP和SVR（p < 0.05），并增加了左心室最大dP/dt、CI和SVI（p < 0.05）。卡托普利+GH/IGF-1治疗的动物中CI和SVI的增加显著大于单独使用卡托普利治疗的动物（p < 0.05）。卡托普利+GH/IGF-1组保留了卡托普利在减轻心肌肥厚方面的有益作用。结果表明，GH/IGF-1和卡托普利可通过独立且互补的机制改善充血性心力衰竭的心脏功能。
